Asklepios BioPharmaceutical, Inc. (AskBio)
52 articles with Asklepios BioPharmaceutical, Inc. (AskBio)
-
AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
6/28/2021
Asklepios BioPharmaceutical , Inc. announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for the LION-101 gene therapy program.
-
The U.S. FDA granted Fast Track Designation to three biopharma companies for the treatment of LGMD, episodic bleeding and leukemia.
-
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
Bayer is taking multiple shots at Parkinson’s disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.
-
AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA
5/25/2021
- LGMD2I/R9 is a Rare Form of Muscular Dystrophy with No Approved Therapies - - Phase 1/2 Clinical Study Expected to Begin Dosing in 1H 2022 -
-
LION-101 is a novel recombinant AAV being developed as a one-time intravenous infusion for the treatment of adult and adolescent patients with Limb-Girdle Muscular Dystrophy Type 2I/R9.
-
Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program
4/29/2021
– Methylmalonic Acidemia ( MMA) program to become wholly-owned by Selecta – – Selecta to postpone IND submission until at least the fourth quarter of 2021 – – Empty capsid (SEL-399) study remains on track –
-
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
2/17/2021
– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy –
-
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
1/28/2021
Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company and wholly owned subsidiary of Bayer AG, today announced that the clinical team from Brain Neurotherapy Bio, Inc., a gene therapy company based in Columbus, Ohio, has joined AskBio to expand its clinical pipeline for the treatment of neurodegenerative disorders.
-
Gene Therapy Leader Katherine High Joins AskBio as President, Therapeutics
1/12/2021
Asklepios BioPharmaceutical, Inc., a clinical-stage adeno-associated virus gene therapy company and wholly owned subsidiary of Bayer AG, announced that Katherine High, MD, has joined the company in the newly formed role of President, Therapeutics and will also serve on its Board of Directors.
-
AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal
12/11/2020
Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that its President and Chief Scientific Officer, Jude Samulski, PhD, has been honored as Triangle Business Journal’s (TBJ) 2020 Business Person of the Year. “My passion to help people is reflected in the work we do every day to bring much-needed treatments to patients and their families who ar
-
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101 has obtained both orphan drug designation and rare pediatric disease designation from the FDA
11/19/2020
Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia due to methylmalonyl-CoA mutase gene mutations.
-
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101
11/19/2020
Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations. MMA-101 previously received rare pediatric disease de
-
Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy
10/26/2020
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need
-
Bayer is paying $2 billion upfront for AskBio's AAV-based gene therapy pipeline of treatments for Pompe disease, among others, and could pay an additional $2 billion in potential milestones.
-
BioSpace Movers & Shakers, Sept. 18
9/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Kellie Sears Named AskBio Chief Human Resources Officer
9/16/2020
Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Kellie Sears has been appointed to its executive team as Chief Human Resources Officer. She joins AskBio from Allergan and will have responsibility for all aspects of human capital management, including talent acquisition and administration, leadership development, compensation and benefits
-
AskBio CSO Jude Samulski Receives 2020 Life Sciences Award from the Triangle Business Journal
8/24/2020
Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that its president and chief scientific officer, Jude Samulski, PhD, has been honored as one of the Triangle Business Journal’s (TBJ) 2020 Life Sciences Award winners. The award recognizes individuals and research organizations at the forefront of innovation in the growing Triangle-area life
-
AskBio CSO Jude Samulski Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
8/3/2020
Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company, announced that Jude Samulski, PhD, AskBio’s President and Chief Scientific Officer, has been named to PharmaVOICE magazine’s annual list of the 100 most inspiring and entrepreneurial leaders in the life sciences industry.